Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in survival, even in patients with advanced cancers. Despite the good clinical results, a certain percentage of patients do not respond to this kind of immunotherapy. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Camelliti, Simone, Le Noci, Valentino, Bianchi, Francesca, Moscheni, Claudia, Arnaboldi, Francesca, Gagliano, Nicoletta, Balsari, Andrea, Garassino, Marina Chiara, Tagliabue, Elda, Sfondrini, Lucia, Sommariva, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650183/
https://www.ncbi.nlm.nih.gov/pubmed/33168050
http://dx.doi.org/10.1186/s13046-020-01721-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650183/
https://www.ncbi.nlm.nih.gov/pubmed/33168050
http://dx.doi.org/10.1186/s13046-020-01721-9

Ejemplares similares